Team

Dr. Biju Benjamin is a drug discovery and translational research scientist with core strengths in DMPK, and PK-PD modelling with sound background of biology and clinical pharmacology. He brings along a balanced blend of wet-lab experimental, data analysis and mathematical modelling skills in drug discovery and early development covering therapeutic areas of cancer, diabetes, anti-infectives, inflammation, allergy, immunology and CNS disorders. A rich wet lab research experience spanning over a decade supplemented by translational research and PKPD modelling experience of more than five years providing an end to end visibility of the drug discovery and early clinical development process. Dr. Benjamin led the ADME and PK-PD functions being part of ‘early development engine’ Vanthys, a joint venture between Eli-Lilly and Jubilant (Vanthys), and various functional roles in drug discovery with leading indian research companies Ranbaxy and Dr. Reddys.

Biju Benjamin is a Ph.D from BITS, Pilani and has a Masters degree in Pharmacology from MAHE, Manipal. He is also the primary author or contributor to 13 publications or poster presentations, spanning areas of bioanalysis, pharmacology and pharmacokinetics.

Dr. Darshan spent 10 years with AstraZeneca in his roles providing strategic inputs to drug discovery and development in India and UK. At AstraZeneca UK, as the Global Drug Safety Physician he was member of Clinical Development Teams for Cardiovascular and Inflammation therapy areas in First in Man studies to Phase III program. He represented the company at the FDA and EMEA to discuss the End of Phase II program and design of Phase III study in development of Ticagrelor.

In 2007 Darshan was part of the team that set up Sciformix Technologies, a service provider in Clinical Data Management, Biostatistics and Medical Writing. In 2010, Darshan was involved in the due diligence process and development of new pharmaceutical and biological products at Vanthys Pharmaceutical Development Pvt. Ltd.

Darshan Bhatt is a postgraduate in medicine and holds an M.Phil. degree in Hospitals and Health Systems Management. Darshan has chaired the Data & Safety Monitoring Board for several clinical studies for different clients.

Professor Serge Guzy (affiliate Professor with UMB,UCD,UFL and UMN) acquired his chemical engineering degree in 1982 from the University of Brussels and received his master degree in chemistry and biophysics in 1985 from the Weizmann Institute. Serge obtained his Doctorate in biomedical engineering on 1990 from the Technion and one year later got his post-doctorate from UC Berkeley in chemical engineering and held a faculty position UCSF School of Pharmacy between 1991-1996. Since that time Serge served as a consultant for Pharsight, headed the Pharmacometric department at XOMA, Biotech, and founded POP-PHARM with the end of providing PK/PD consulting and software development in support of drug development. With 25 years of experience with modeling and simulation, Serge Guzy is also the President, CEO of POP-PHARM, a consulting and software Development Company founded in 2004. He established new methods for statistical population approaches in drug development, based on Monte Carlo simulation algorithms. The resulting MC-PEM methodology and Population software development made him now internationally recognized. These new tools have already been well utilized in drug development, from the early stage of antibody discovery and lead selection programs as a useful tool to guide antibody design goals and inform teams for better decision making , as well as in clinical development as a tool for guiding optimally new trial designs.

Serge Guzy has consulted for more than 70 companies from start up to large pharmaceutical companies. His area of expertise is Pharmacometrics with emphasis on the statistical aspects of Pharmacometrics and use of Pharmacometrics for combined PK/PD and categorical/count/time to events clinical end point. Serge Guzy consults companies starting from preclinical up to end of Phase 3. The modeling and simulation aspects refer to data driven model building with emphasis on system identifiability. His expertise covers complex systems involving for example continuous markov processes, item response theory, discrete markov processes, distributed delay systems and general multiple time to event systems.